CDC, Arthritis Foundation seek to raise awareness about osteoarthritis
WASHINGTON The Centers for Disease Control and Prevention and the Arthritis Foundation in early February announced a major initiative to dramatically reduce the impact of osteoarthritis on Americans. In conjunction with the announcement, the Arthritis Foundation and the Ad Council are unveiling a national public awareness campaign in response to the recommendations outlined in the action plan, "A National Public Health Agenda for Osteoarthritis."
The Agenda is the result of an 18-month effort by the CDC and the Arthritis Foundation that included the development of two working groups, one focusing on research interventions and the other on policy/communications efforts, and a major summit that brought together more than 75 stakeholders to determine the best strategies for reducing the impact of osteoarthritis.
“This important report will help the public health community speak with a unified voice and focus our collective efforts on actions that we know will make a difference in the lives of people suffering from osteoarthritis,” stated Ursula Bauer, director of CDC’s National Center for Chronic Disease Prevention and Health Promotion.
Already the nation’s most common cause of disability, the impact of arthritis is slated to increase in the decades to come. One-in -ive adults in the United States (46 million people) has arthritis and an estimated 67 million people will be affected by 2030.
Osteoarthritis, the most common form of arthritis, is a serious and painful joint disease that currently affects nearly 27 million people in the United States and costs an estimated $5,700 annually per person living with the disease. With the combination of inactivity, obesity, injury and the aging of Americans, the rising prevalence of osteoarthritis is expected to escalate the severe health and economic effects of this disease.
Study finds Ulesfia effectively kills head lice
HOBOKEN, N.J. A new non-neurotoxic treatment for head lice has been found to have an average of 91.2% treatment success rate after one week, and to be safe in humans from 6 months of age and up, according to a study published in the latest issue of Pediatric Dermatology.
Benzyl Alcohol Lotion 5% (branded Ulesfia) works by suffocating lice. Unlike commonly used asphyxiant remedies, scanning electron microscopy appears to indicate that benzyl alcohol lotion effectively asphyxiates lice by “stunning” the spiracles open, allowing the lotion, comprised of mineral oil and other inactive ingredients, to infiltrate the “honeycomb” respiratory apparatus and kill lice.
“Existing over-the-counter head lice treatments contain neurotoxic pesticides as active ingredients, resulting in potential toxicity and other problems, including lengthy applications, odor, ineffective treatment,” stated study author Terri Meinking of Global Health Associates. “Resistance has also become a problem now that lice have had such prolonged exposure to these products.”
E-cigarette maker welcomes FDA challenge
MIAMI Despite the ongoing battle between the Food and Drug Administration and electronic cigarette makers, one manufacturer welcomes the challenge as a chance to present its product as a healthier alternative to traditional tobacco.
Green Smoke said it has created an electronic cigarette designed to simulate the smoking experience without carcinogenics. Instead, it emits an odorless vapor of mostly steam, with ingredients like nicotine, water, propylene glycol (an additive used in cake mixes) and others. The nicotine also is available in different strengths.
The company also added that the price for the electronic cigarettes are more cost-efficient than regular tobacco products, with cigarette starter kits ranging from $109 to $270. The starter kits include nicotine cartridges, rechargeable cigarette batteries, home charger and more.